Abstract
The identification of autophosphorylation of the insulin receptor as a pivotal component in the signal transduction induced by insulin, initiated the hunt to identify the tyrosine phosphatase(s) that were responsible for regulating dephosphorylation, and thus inactivation of the receptor. Compelling evidence for the existence of an insulin receptor specific PTP has come from the remarkable phenotype of the PTP1B deficient mouse. PTP1B deficient mice display an insulin sensitive phenotype and are able to maintain glucose homeostasis with about half the level of circulating insulin. In response to insulin administration PTP1B deficient mice have a significant increase in insulin receptor phosphorylation in liver and muscle compared to wild type controls. Unexpectedly these animals were also resistant to diet induced obesity. These observations strongly support PTP1B as a negative regulator of insulin action, thereby making it an ideal therapeutic target for intervention in type 2 diabetes and obesity.
Keywords: Protein Tyrosine Phosphatase, Diabetes and Obesity, autophosphorylation, tyrosine phosphatase, phenotype
Current Topics in Medicinal Chemistry
Title: Protein Tyrosine Phosphatase 1B: A Novel Target for Type 2 Diabetes and Obesity
Volume: 3 Issue: 7
Author(s): Chidambaram Ramachandran and Brian P. Kennedy
Affiliation:
Keywords: Protein Tyrosine Phosphatase, Diabetes and Obesity, autophosphorylation, tyrosine phosphatase, phenotype
Abstract: The identification of autophosphorylation of the insulin receptor as a pivotal component in the signal transduction induced by insulin, initiated the hunt to identify the tyrosine phosphatase(s) that were responsible for regulating dephosphorylation, and thus inactivation of the receptor. Compelling evidence for the existence of an insulin receptor specific PTP has come from the remarkable phenotype of the PTP1B deficient mouse. PTP1B deficient mice display an insulin sensitive phenotype and are able to maintain glucose homeostasis with about half the level of circulating insulin. In response to insulin administration PTP1B deficient mice have a significant increase in insulin receptor phosphorylation in liver and muscle compared to wild type controls. Unexpectedly these animals were also resistant to diet induced obesity. These observations strongly support PTP1B as a negative regulator of insulin action, thereby making it an ideal therapeutic target for intervention in type 2 diabetes and obesity.
Export Options
About this article
Cite this article as:
Ramachandran Chidambaram and Kennedy P. Brian, Protein Tyrosine Phosphatase 1B: A Novel Target for Type 2 Diabetes and Obesity, Current Topics in Medicinal Chemistry 2003; 3 (7) . https://dx.doi.org/10.2174/1568026033452276
DOI https://dx.doi.org/10.2174/1568026033452276 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Delivery Technologies for Protein and Peptide Therapeutics
Current Pharmaceutical Biotechnology Conversion of TBAb Response to TSAb Response by Anti-human IgG Antibody
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Strategies to Modulate the NF-κB and JNK Signal Transduction Network
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Impact of Uncontrolled Hypertension on the Longitudinal Systolic Function of the Left Ventricle
Current Hypertension Reviews Acylhydrazones Contribute to Serum Glucose Homeostasis Through Dual Physiological Targets
Current Topics in Medicinal Chemistry Screening GLP-1 Receptor Ligands from Natural Products in Herbs through High-Content Technique
Combinatorial Chemistry & High Throughput Screening Pneumococcal Infections at Hajj: Current Knowledge Gaps
Infectious Disorders - Drug Targets Antioxidant Activity of Uva di Troia Canosina: Comparison of Two Extraction Methods
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) A Perspective to the Correlation Between Brain Insulin Resistance and Alzheimer: Medicinal Chemistry Approach
Current Diabetes Reviews Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block
Current Vascular Pharmacology Osteoimmunology and Beyond
Current Medicinal Chemistry Ex Vivo Gene Transfer for Improvement of Transplanted Pancreatic Islet Viability and Function
Current Pharmaceutical Design Role of Hyperglycaemia in Pathogenesis of Diabetic Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Exploring the Role of “Brahmi” (Bacopa monnieri and Centella asiatica) in Brain Function and Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) PEDF & Stem Cells: Niche vs. Nurture
Current Drug Delivery Patent Annotations
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) AICD Nuclear Signaling and Its Possible Contribution to Alzheimers Disease
Current Alzheimer Research Alzheimers Disease: SPECT and PET Tracers for Beta-Amyloid Imaging
Current Alzheimer Research Overcoming the Limitation of GWAS Platforms Using Systems Biology Approach
Current Bioinformatics Hepatic Nuclear Factor-4, a Key Transcription Factor at the Crossroads Between Architecture and Function of Epithelia
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)